Randomized controlled trialHumanClinical Trial, Phase III

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

Lancet (London, England), 2026 Mar 21. Rosenstock J, Yabe D, Cox D and 6 others.

Study type

Randomized controlled trial · Clinical Trial, Phase III

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Lancet (London, England)

Published

2026 Mar 21

PubMed

PMID 41765029 ↗

DOI

10.1016/S0140-6736(26)00202-3 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Orforglipron →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AdultAgedFemaleHumansMaleMiddle AgedAdministration, OralDiabetes Mellitus, Type 2Drug Administration ScheduleGlycated HemoglobinHypoglycemic AgentsTreatment Outcome

Other papers on Orforglipron

Randomized controlled trial · 2026

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Randomized controlled trial · 2026

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial

Randomized controlled trial · 2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Randomized controlled trial · 2025

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

Randomized controlled trial · 2023

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Randomized controlled trial · 2023

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page